secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2022-02-18T23:59:59+00:00
Accession:  0001628280-22-003178
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics promotes Garry Neil to CEO and Chris Sullivan to CFO, replaces Cola and Greenway
--------------------------------------------------------------------------------

- Garry Neil appointed CEO from CSO; base salary $475K/yr, option for 1M shares vesting 4 years.
- Chris Sullivan appointed CFO from CAO; base salary $350K/yr, $50K bonus, option for 400K shares.
- Former CEO Michael Cola and CFO Schond Greenway terminated effective Feb 14, 2022.
- Neil serves as Chairman of Arena Pharmaceuticals (ARNA), a ~$6B Nasdaq biotech.
- Sullivan previously helped raise ~$80M in gross proceeds as interim CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828022003178/0001628280-22-003178-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828022003178/avtx-20220214.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-003178

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer